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ABSTRACT
Spinal muscular atrophy (SMA) is a devastating neuromuscular disorder
characterized by loss of motor neurons and muscle atrophy, generally
presenting in childhood. SMA is caused by low levels of the survival
motor neuron protein (SMN) due to inactivating mutations in the
encoding geneSMN1. A second duplicated gene,SMN2, produces very
little but sufficient functional protein for survival. Therapeutic strategies to
increase SMNare in clinical trials, and the firstSMN2-directed antisense
oligonucleotide (ASO) therapy has recently been licensed. However,
several factors suggest that complementary strategies may be needed
for the long-term maintenance of neuromuscular and other functions
in SMA patients. Pre-clinical SMA models demonstrate that the
requirement for SMN protein is highest when the structural
connections of the neuromuscular system are being established, from
late fetal life throughout infancy. Augmenting SMNmay not address the
slow neurodegenerative process underlying progressive functional
decline beyond childhood in less severe types of SMA. Furthermore,
individuals receiving SMN-based treatments may be vulnerable to
delayed symptoms if rescue of the neuromuscular system is incomplete.
Finally, a large number of older patients living with SMA do not fulfill the
present criteria for inclusion in gene therapy and ASO clinical trials, and
may not benefit from SMN-inducing treatments. Therefore, a
comprehensive whole-lifespan approach to SMA therapy is required
that includes both SMN-dependent and SMN-independent strategies
that treat theCNSand periphery. Here, we review the range of non-SMN
pathways implicated in SMA pathophysiology and discuss how various
model systems can serve as valuable tools for SMA drug discovery.
KEY WORDS: Animal models, Cellular models, Combinatorial
therapies, Skeletal muscle, Spinal muscular atrophy, Survival
motor neuron
Introduction
Spinal muscular atrophy (SMA) is the most common genetic disease
resulting in death in infancy, affecting approximately 1 in 6000 to 1
in 10,000 births (Crawford and Pardo, 1996). This autosomal
recessive disorder, resulting from the loss-of-function of the
survival motor neuron 1 (SMN1) gene, is characterized by loss of
spinal cord motor neurons, muscular atrophy, neuromuscular
junction (NMJ) denervation and paralysis (Crawford and Pardo,
1996; Kariya et al., 2008; Kong et al., 2009; Lefebvre et al., 1995;
Murray et al., 2008). SMN1 is highly conserved and present as a
single copy in the genome of all eukaryotic organisms (Bergin et al.,
1997; Miguel-Aliaga et al., 1999, 2000; Paushkin et al., 2000). In
humans, however, a genomic duplication has given rise to a second
gene, SMN2 (Lefebvre et al., 1995; Rochette et al., 2001). A crucial
C-to-T substitution at position 6 of exon 7 in SMN2, which occurs in
all individuals, leads to the aberrant splicing of exon 7 and the
subsequent production of an unstable SMNΔ7 protein (Lorson et al.,
1999; Monani et al., 2000). An important sequence in intron 7 of
SMN2, termed intron splicing silence N1 (ISS-N1) has been
demonstrated to further favour the exclusion of exon 7 in the
transcript (Singh et al., 2006). Thus, the telomeric SMN1 copy gives
rise to the full-length (FL) SMN protein while the centromeric
SMN2 copy predominantly produces the SMNΔ7 protein. However,
the SMN2 gene always generates a small amount of functional
protein, which maintains viability, as homozygous deletion of
SMN1 is uniformly lethal (Gennarelli et al., 1995; Lefebvre et al.,
1995). Deletions or intragenic mutations in SMN1 are found in all
forms of SMA, with SMN2 acting to modulate the disease severity
through variation in its copy number (Gennarelli et al., 1995;
Lefebvre et al., 1995) (Fig. 1). As the number of copies of SMN2
increases, so does the quantity of stable FL-SMN protein produced.
Thus, the variation in clinical severity seen in SMA is mostly
explained by the total level of residual SMN protein.
SMA is clinically heterogeneous and has been categorized into
five types (0-IV) based on age of onset, severity of motor decline
and life expectancy. The term ‘Type 0’, in which the minimal
complement of one SMN2 gene is present, describes SMA with a
clear in utero onset, arthrygryphosis (limited joint contracture) and
complex motor and sensory nerve deficits, and death before or just
after birth. Type I SMA patients display the most severe symptoms,
with death in infancy if invasive ventilation is not implemented.
Types II and III have a later childhood onset and are associated with
survival into adulthood, and the potential for a normal lifespan,
albeit with considerable physical disability (Munsat and Davies,
1992; Pearn, 1980). The clinical course of Type II and III patients
living with SMA is characterized by long periods of relative stability
with superimposed periods of accelerated functional decline, for
example during the pubertal growth spurt, and a subsequent long
period of slowly progressive age-related loss of motor function
(Kaufmann et al., 2012). Advances in respiratory, musculoskeletal
and nutritional care mean that greater numbers of patients with Type
I SMA are surviving beyond infancy. Most SMA Type II patients
are living full lives into adulthood and Type III SMA is, in the
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majority of cases, associated with a normal lifespan (Rudnik-
Schöneborn et al., 2001). The clinical and molecular features of the
five types of SMA are presented in Table 1. Given the range of
severity and ages of onset, it will be necessary for any therapeutic
strategy to address the needs of all individuals affected by SMA,
from infancy to adulthood.
The SMN protein is ubiquitously expressed and is localized in the
cytoplasm (Liu and Dreyfuss, 1996), neuronal growth cones (Fan and
Simard, 2002), neuronal extensions (Fallini et al., 2010), the nucleolus
(Charroux et al., 2000; Wehner et al., 2002) and in punctate nuclear
structures called Gemini of coiled bodies (Gems) and Cajal bodies
(Carvalho et al., 1999; Liu andDreyfuss, 1996). The SMNprotein has
thus been attributed several key regulatory cellular functions in
neuronal cells, including roles in RNAmetabolism [specifically small
nuclear ribonucleoproteins (snRNPs)] (Li et al., 2014), actin
cytoskeleton dynamics (Hensel and Claus, 2017), mRNA transport
(Donlin-Asp et al., 2016), ubiquitin homeostasis (Groen and
Gillingwater, 2015), bioenergetics pathways (Boyd et al., 2017) and
synaptic vesicle release (Kong et al., 2009) (Fig. 2). Importantly, to
date, noneof these roleshas been identified as being solely responsible
for SMA pathophysiology.
The most advanced therapies currently in clinical trials for SMA
are aimed at increasing FL SMN either by exogenously expressing
SMN1 or upregulating FL SMN2 production (d’Ydewalle and
Sumner, 2015). Unless these current SMN-dependent approaches
can be given pre-symptomatically, when motor neuron dysfunction
may still be reversible, and delivered with a very high level of
efficiency to drastically induce SMN levels in spinal cord motor
neurons, it is likely that the progressive neurodegenerative process
will not be completely abrogated but simply slowed down. Thus,
treated SMA patients may be vulnerable to a delayed deterioration
of the neuromuscular system. There are also a large number of older
children and adults living with SMA who do not fulfill the present
criteria for inclusion (on the grounds of age and various clinical
parameters) in the ongoing clinical trials and for whom it is not
currently clear that SMN-inducing treatments will be beneficial
Fig. 1. SMN1 and SMN2 contribute to spinal muscular atrophy
(SMA). In healthy individuals, the survival motor neuron 1 (SMN1)
gene produces 100% full length (FL) SMN protein while the SMN2
gene produces ∼10% FL SMN and ∼90% of a non-functional
product that lacks exon 7 (SMNΔ7) due to aberrant alternative
splicing. In SMA patients, the SMN1 gene is lost due to mutations or
deletions. SMN2 remains and the small amount of FL SMN is
sufficient for survival. The number of SMN2 copies correlates with
disease severity, with a lower copy number being linked to more
severe types of SMA.
Table 1. Clinical and molecular features of SMA sub-types
Type of SMA
0 I II III IV
SMN2 copy number* 1 2 3 3-5 3-5
Age of onset In utero Majority by 6 months 6-12 months After 18 months (IIIa:
<3 years, IIIb:
>3 years)
Adulthood
Key clinical features Widespread motor and
sensory neuronal loss
Contractures
High incidence of
congenital cardiac
defects
Neonatal hypotonia
Poor feeding and head
control
Respiratory insufficiency
Never develop ability to roll
or sit unaided
Sit unsupported
Never walk
Respiratory muscle
weakness
Walk unaided, even if
briefly
Progressive proximal
weakness
Lower limb
predominance
Natural history Peri-natal death 50% death by 12 months
90% death by 24 months
without invasive ventilation
Life expectancy
30-50 years
depending on
respiratory function
Loss of ambulation very
variable (from
childhood to late life)
Respiratory involvement
uncommon
Life expectancy near
normal
Slow progression
Ambulation
maintained
Normal lifespan
*All SMA patients, regardless of type have no functional copies ofSMN1; the number ofSMN2 copies in unaffected individuals (carriers or non-carriers) can range
from 2 to 5.
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because of the significant and irreversible SMN-related
neuromuscular decline that is already established. Furthermore, it
has become evident that SMA pathophysiology extends beyond the
neuromuscular system, whereby numerous peripheral organs and
tissues demonstrate pathological changes in pre-clinical models and
patients (Hamilton and Gillingwater, 2013). Therapies that improve
neuromuscular function as well as maintain lifelong general health
of people living with SMA are therefore a major priority and an
unmet clinical need.
As the first successful SMN-targeted therapeutic approaches are
emerging into the clinical arena (Finkel et al., 2016; Gillingwater,
2016), we review here how to best move forward in the development
of combinatorial therapeutic approaches for SMA that, ideally,
would target the CNS and the periphery, operating via SMN-
dependent and SMN-independent processes. We will firstly
consider the various existing and alternative experimental models
that could be used to identify novel SMA therapeutic targets. We
will then discuss how the current SMN-specific compounds
presently in clinical trials inform the potential development of
treatments aimed at non-SMN targets in non-CNS tissues. Finally,
we will expand on the idea of developing drug discovery and
delivery approaches that enable systemic delivery of therapies.
Advantages and limitations of current animal and cell
models
Animal models
A range of in vivo model systems have been developed to aid
understanding of the pathogenesis of SMA and to test the efficacy
of therapies. The similarities in anatomy and physiology to the
human neuromuscular system, coupled with the ease of genetic
manipulation, mean that the mouse has been an extremely valuable
model for exploring the basic pathogenesis and evaluating potential
treatments for SMA. Various mouse models have been developed
over the years, displaying differing ranges of disease severity. While
the complete knockout (Smn−/−) is embryonic lethal (Schrank et al.,
1997), the heterozygous animals (Smn+/−) do not develop a typical
SMA phenotype (Bowerman et al., 2014; Schrank et al., 1997),
which is in accordancewith data demonstrating that loss of∼85% of
normal Smn levels is required to reflect an SMA phenotype in mice
(Bowerman et al., 2012a). Genetic modifications were thus
integrated in the Smn–/– mice to allow their survival, whilst still
retaining the criteria for an SMA model. The severely afflicted
Smn–/–;SMN2 mice (Hsieh-Li et al., 2000; Monani et al., 2000)
harbor a human SMN2 transgene that produces the typical∼15% FL
SMN2 transcript, whereas the Smn–/–;SMN2;SMNΔ7/Δ7 transgenic
mice (Le et al., 2005) additionally express the partially functional
human SMNΔ7 protein, which confers an increase in survival. Both
these severe SMA mouse models typically do not survive past the
first two post-natal weeks and therefore do not reflect the chronic
phase of the disease, making them suitable for modelling only
severe infantile SMA. This limitation means that these mice are also
unsuitable for the evaluation of non-SMN therapies that may benefit
some aspects of SMA pathology. In addition, severe SMA mouse
models do not allow for the long-term evaluation of extra-CNS
defects that might emerge over time in people living with Type II, III
and IV SMA. To address this, animals that have a significantly longer
asymptomatic phase have been developed. Smn2B/–mice (Bowerman
et al., 2012a; Hammond et al., 2010) are an intermediate model with
an average lifespan of 30 days. These mice carry an endogenous
mutation within the murine Smn gene that mimics the human SMN2
gene by principally producing SMNΔ7 transcripts. Recently, longer-
lived intermediate models were generated by administration of
sub-optimal doses of exon 7 inclusion-promoting ISS-N1 antisense
Fig. 2. Localization of the survival motor neuron (SMN)
protein in neuronal cells and associated general cellular
functions. SMN regulates small nuclear ribonucleoprotein
(snRNP) biogenesis, maturation and recycling in Gemini of coiled
bodies (Gems) and Cajal bodies; ribosome biogenesis in
nucleolus; snRNP biogenesis and actin dynamics in the
cytoplasm; mRNA transport in axons; actin dynamics and vesicle
release in the synpase.
Box 1. Glossary
AAV: adeno-associated virus. A small DNA virus that infects humans
and other primate species without causing disease.
ASO: antisense oligonucleotide. A synthetic polymer, typically 15-20
nucleotides long and complementary to the sense sequence of a target
mRNA.
BBB: blood-brain barrier. A highly selective semi-permeable endothelial
cell barrier separating the circulating blood from the brain in the central
nervous system.
CPP: cell-penetrating peptide. A short peptide that facilitates cellular
uptake of molecules.
Discordant: in disagreement.
FDA: Food and Drug Administration of the United States Department of
Health and Human Services; responsible for protecting and promoting
public health.
Hypomorphic: genetic mutation causing partial loss of function.
Intracerebroventricular: direct injection into the ventricular system
(i.e. into the cerebral ventricles) of the brain.
Intrathecal: direct injection into the sub-arachnoid space so that a drug
reaches the cerebrospinal fluid.
NMJ: neuromuscular junction. The chemical synapse between a motor
neuron and a muscle fibre.
SMN: survival motor neuron protein encoded by the human SMN1 and
SMN2 genes that are ubiquitously expressed in most cells and tissues
with a range of cell-specific and housekeeping functions.
945
REVIEW Disease Models & Mechanisms (2017) 10, 943-954 doi:10.1242/dmm.030148
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
oligonucleotides (ASOs, Box 1) to human SMN2-carrying SMA
mice (to promote an insufficient increase of FL-SMN for complete
rescue) (Hosseinibarkooie et al., 2016; Zhou et al., 2015). Mouse
models thus remain an important system for augmenting our
understanding of the SMA disease process and in the evaluation of
potential therapeutic approaches.
More targeted hypotheses about the role of SMN and its
interaction with specific proteins can be successfully explored in
invertebrates, particularlyDrosophila (fruit flies) (Chan et al., 2003;
Chang et al., 2008) and Caenorhabditis elegans (Burt et al., 2006),
and genetically tractable vertebrate model organisms that present a
developmental phenotype, such as zebrafish (Hao et al., 2011;
McWhorter et al., 2003). However, these models may display
phenotypes that differ greatly from what is observed in mouse
models and SMA patients. The locomotor and motility defects
characterized in Drosophila larval SMA models (Praveen et al.,
2012, 2014) can only have an indirect relationship to the disruptions
in neuromuscular function that occur in patients. In zebrafish
models of SMA generated by antisense morpholinos or maternal
zygotic genetic mutations (Hao et al., 2013; McWhorter et al.,
2003), developing motor axons and dendrites display outgrowth and
branching defects, whereas in mouse and human, SMAmotor axons
correctly reach the target muscle and form the NMJ, followed by
denervation of the muscle as the disease progresses (Ling et al.,
2012). Nevertheless, such model systems are more efficient than
mammalian models for high-throughput screening and are likely to
have significant advantages if utilized efficiently and thoughtfully.
Finally, there have also been initiatives to develop large animal
models for SMA, particularly for the evaluation of the delivery,
benefits and toxicity of clinical-grade therapeutics. Specifically,
endogenous and exogenous genetic modifications have been
introduced in the pig to generate a porcine SMA model (Duque
et al., 2015; Towne et al., 2010). More work is needed to evaluate
whether the pig will become the pre-clinical model of choice for
therapeutic assessment.
Cellular models
There are obvious limitations in the extent to which mouse models
and the other in vivomodels described above might be predictive of
effects in humans, owing to inherent species-specific differences in
cellular function. The inability to directly study neurons in
individuals affected by a neurological disorder such as SMA has
been a key impediment to understanding basic pathological
mechanisms, particularly those occurring early in the disease
process. Recent developments in stem cell technology have
substantially expanded the range of cellular models available in
motor neuron disease research by allowing the direct observation of
pathological mechanisms in neurons derived from induced
pluripotent stem cells (iPSCs) obtained from fibroblasts derived
from affected individuals. SMA was the first neurological disorder
in which a disease-relevant phenotype was demonstrated in
iPSC-derived motor neurons (Ebert et al., 2009).
Beyond neurons, other cell types have been demonstrated to
contribute to SMA pathology, as described below. iPSCs can be
converted into pancreatic and cardiac cells, and thus represent an even
more powerful tool, as these cell lines can be studied separately or in
co-culture systems that mimic the dynamic interaction that exists in
the human body (De Vos et al., 2016). Furthermore, iPSCs can also
be used to generate endothelial cells (Lippmann et al., 2014) to model
the blood-brain barrier (BBB; Box 1) that protects the CNS, but also
limits the entry of therapeutic compounds (Abbott, 2013; Pardridge,
2005), thus allowing screening of novel and established drugs for the
ability to cross the BBB as well as compare the properties of SMA
and healthy endothelial cells.
iPSC-derived motor neurons can be generated from families in
which genotypically matched individuals are discordant for the SMA
phenotype, to serve as a tool to identify disease modifiers (Boza-
Morán et al., 2015). Similarly, iPSCs can be generated fromType I, II
and III patients, allowing the exploration of the impact of small
changes in SMN expression at a cellular level. While iPSCs hold a lot
of promise, experimental caveats include heterogeneity of the cell
populations derived, as well as the limitations of studying cells in
culture, isolated from other tissues within the context of the whole
organism (Rouhani et al., 2014; De Filippis et al., 2017; Ebert et al.,
2012). Nevertheless, iPSC-based models will give new insights into
disease mechanisms and will also serve as a screening and validation
tool for potential therapies identified in model organisms, especially
as part of an experimental workflow designed to identify novel
molecular targets anddrugs and evaluate their combinatorial potential.
Indeed, testing of candidate therapies across multiple platforms will
most likely be key to the efficient and successful advancement of
complementary therapeutic approaches (Fig. 3).
Current SMN-targeted trials: early successes
At the forefront of SMA translational research are efforts now
entering clinical trials for therapies that promote SMN2 exon 7
inclusion via ISS-N1 inhibition, that increase FL SMN2
transcription (small molecules) or that directly replace SMN1
(viral gene therapy) (Table 2) (d’Ydewalle and Sumner, 2015). Two
decades of basic research characterizing the molecular basis of exon
7 splicing (Singh et al., 2017) have recently culminated in the first
successful clinical trial of an ASO therapy (nusinersen, commercial
name Spinraza) developed and commercialized by Ionis
Pharmaceuticals and Biogen (Finkel et al., 2016; Gillingwater,
2016). Not only did intrathecal delivery of nusinersen improve some
disease symptoms in Type I patients, but there was also evidence
that levels of FL SMN were increased in spinal motor neurons of
treated individuals. Although this was an open-label (unblinded)
trial, treatment can be cautiously compared favourably to the
devastating natural history of Type I SMA patients where the
majority of children have died or become ventilator-dependent
before the age of 12 months. Whilst the results of an ongoing Phase
III study in a larger cohort of patients are awaited, the drug was
approved in December 2016 by the United States Food and Drug
Administration (US FDA) for all types of SMA based on the
strength of the existing data. Likewise, nusinersen was
recommended for European Union approval by the EMA in April
2017 and given marketing authorization in June 2017.
The ASO therapeutic approach, however, requires invasive
intrathecal and intracerebroventricular administration for adequate
delivery to the CNS, thus not addressing the issue of expression
levels of FL SMN required in peripheral tissues, which are also
potentially key contributors to SMA pathology (see below). A non-
replicating adeno-associated virus (AAV9) vector has been
developed by AveXis to deliver a functional copy of a human
SMN1 gene. A potential advantage of this approach is that AAV9
crosses the perinatal BBB, allowing a single intravenous dose to
ensure widespread systemic delivery. A Phase 1 clinical trial is now
underway. Small molecules that increase FL SMN2 expression can
also be administered systemically but their ability to cross the BBB
may be limited and their exact mode of action needs to be deciphered
to minimize potential off-target adverse effects. Small molecules
targeting SMN2 developed by Novartis Pharmaceuticals and
Hoffmann-La Roche are currently in clinical trials.
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Given that nusinersen and other small molecules act on SMN2, the
evaluation of their activity in pre-clinical studies was limited to
severe SMN2-harboring mice and patient fibroblasts (Pinard et al.,
2017; Ratni et al., 2016; Singh et al., 2017). Similarly, the efficiency
of AAV9-SMN1 to increase SMN expression was demonstrated in
micewith severe SMA (Armbruster et al., 2016; Passini et al., 2010).
Whilst use of additional models such as Drosophila and zebrafish
maynot be relevant in these instances, assessing the activity of SMN-
dependent approaches in iPSC-derived motor neurons, in vitroBBB
models and other cell types may help shed light on cell-specific
activity and efficiencyof these various drugs,which could help in the
optimization of their respective dosing regimens.
Expanding the repertoire of targets to non-neuronal tissues
Although SMA has generally been considered as an archetypal
disorder of selective motor neuron vulnerability, there is now
abundant evidence that other tissues and cells are either overtly or
sub-clinically affected in SMA patients and animal models
(Hamilton and Gillingwater, 2013), including skeletal muscle
(Boyer et al., 2013; Martínez-Hernández et al., 2009; Mutsaers
et al., 2011; Walker et al., 2008), pancreas (Bowerman et al., 2012c,
2014), liver (Bowerman et al., 2012c, 2014; Szunyogova et al.,
2016), spleen (Deguise et al., 2017; Thomson et al., 2017),
vasculature (Somers et al., 2012, 2016), heart (Bevan et al., 2010;
Heier et al., 2010; Shababi et al., 2010) and Schwann cells
(Aghamaleky Sarvestany et al., 2014; Hao et al., 2015; Hunter et al.,
2014, 2016). The clinical implications of these observations is that
treatment modalities that solely target the nervous system might be
an inadequate long-term therapeutic strategy for SMA, especially in
Type I patients where the consequences of low levels of SMN for
the function of non-CNS tissues beyond infancy is unknown.
To date, a single clinical trial provides evidence for the potential
benefit of non-SMN therapies in the chronic phase of SMA.
Olesoxime is an orally active drug, which is predicted to have
favourable bioenergetics effects as it acts on the outer mitochondrial
membrane to modulate the permeability transition pore opening in
response to oxidative stress. It has a neuroprotective effect in a range
of in vitro and in vivomodels (Bordet et al., 2010). A recent clinical
trial in SMA Type II and III (non-ambulatory) patients did not
achieve its primary endpoint, although it showed some evidence of
disease-stabilising effects using secondary endpoints (Bertini et al.,
2017).
Pharmacological compounds aimed at specifically targeting
skeletal muscle are presently the only non-SMN, non-CNS drugs
in clinical trials for SMA patients. In particular, Cytokinetics Inc.
has developed a fast skeletal troponin activator (CK-2127107) that
is currently in a Phase 2 study in SMA patients. Troponin mediates
muscle contraction (Gresslien and Agewall, 2016), and is
abnormally distributed in skeletal muscle of Type I-III SMA
patients (Stevens et al., 2008). Interestingly, CK-2127107 has not
been evaluated in either pre-clinical or Phase 1 clinical stages as a
therapeutic strategy for SMA. Instead, the drug was investigated in a
rat model of heart failure, where its oral administration resulted in
an overall amelioration of muscle endurance and performance
Fig. 3. A model experimental plan to determine the therapeutic potential of a candidate non-survival motor neuron (SMN) molecular target or drug,
alone and as a combinatorial therapy. Various in vitro and in vivo models such as an in vitro blood-brain barrier (BBB) model, Smn mutant zebrafish,
hypomorphic SMAmousemodels and induced pluripotent stem cell (iPSC)-dervied cells (e.g. motor neurons) could be used to evaluate different activity and efficiency
parameters of the candidate target or drug. Each model system has a particular informative value depending on the candidate target or drug. Finally, the same
experimental paradigm should be followed to assess the synergistic or additive value of combining the non-SMN treatment strategy with an SMN-dependent therapy.
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following exercise (Hwee et al., 2015). A first generation form of the
compound (tirasemtiv or CK-2017357) was also assessed in rodent
neuromuscular models for nemaline myopathy (Lee et al., 2013),
myasthenia gravis (Russell et al., 2012) and amyotrophic lateral
sclerosis (Hwee et al., 2014), demonstrating a significant
improvement in muscle strength in each. Nevertheless, the FDA
has recently granted the Orphan Drug designation to CK-2127107
for the treatment of SMA patients.
Another interesting muscle target is the myostatin-follistatin
pathway, in which myostatin acts as a negative regulator of muscle
growth (McPherron et al., 1997) and is itself inhibited by follistatin
(Lee and McPherron, 2001). Several therapeutics strategies aimed
at modulating this signaling cascade to promote muscle mass
have therefore been evaluated in pathologies characterized by
muscle atrophy, including SMA (Rodino-Klapac et al., 2009).
Administration of recombinant follistatin to Smn–/–;SMN2;
SMNΔ7/Δ7 mice resulted in significant improvement in muscle
mass, gross motor function and lifespan. However, inhibition
of myostatin by genetic (overexpression of follistatin) or
pharmacological [soluble activin receptor IIB (ActRIIB-Fc) that
inhibits the myostatin-promoting receptor] interventions had no
obvious beneficial effects on the phenotype of the same mouse
model (Sumner et al., 2009). Similar negative results were obtained
upon genetically deleting myostatin in severe SMA mice (Rindt
et al., 2012). Conversely, the recent intraperitoneal administration of
a soluble form of ActRIIB encoded by an AAV2/8 viral vector in a
milder model of SMA improved mass, contractile properties and
size of SMN-depleted muscles (Liu et al., 2016). Results from SMA
mouse studies have therefore been varied and the discrepancies may
be due to the differing severities of the models used, the
developmental timing of the approach and the specific targeting/
delivery strategy utilized. Several strategies based on the myostatin-
follistatin pathway are currently in clinical trials for muscle
pathologies such as Duchenne muscular dystrophy (DMD),
Becker muscular dystrophy and inclusion body myositis but have
yet to be initiated for SMA. However, a recent report shows that
serum and muscle biopsies from SMA patients display decreased
expression of myostatin and increased levels of follistatin (Mariot
et al., 2017), suggesting that additional mechanistic insight in the
relevance of targeting this pathway for SMA therapy is required.
Taken together, these findings highlight an important need to
better understand the intrinsic pathologies not only in SMA neurons
but also in muscle and other non-CNS afflicted organs, so that cell-
and tissue-specific treatments can be developed and eventually used
in combination with SMN- and CNS-targeted strategies.
Identifying non-SMN targets to develop combinatorial
therapeutic approaches
SMN-dependent gene therapies will require administration as early
as possible, even pre-symptomatically, to exert the maximum effect
(Bevan et al., 2010; Foust et al., 2010; Valori et al., 2010), and at
present can be expected to reduce disease severity rather than effect
a complete cure. In the absence of a routine screening program for
newborns, the potential benefit may also be limited by the delay in
diagnosis in milder forms, which generally have an insidious onset.
An important step forward would be to develop therapeutic
approaches targeting pathways that reflect the chronic pathological
process in SMA, facilitating treatments that are adjunctive to SMN
replacement therapy to improve and maintain neuromuscular
integrity and function throughout the life of the individual.
One of the first SMN-independent targets to prove beneficial with
respect to potential SMA therapy is the RhoA-ROCK pathway. The
small GTPaseRhoA and its downstream effector, the Ser/Thr protein
kinase ROCK, are key modulators of actin dynamics (Luo et al.,
1997). It has been demonstrated that the RhoA-ROCK pathway is
aberrantly upregulated in SMN-depleted rodent neuronal cells
(Bowerman et al., 2007) and in the spinal cord and skeletal muscle
of Smn2B/–mice (Bowerman et al., 2010, 2012b). Importantly, it was
shown that pharmacological inhibition of ROCK significantly
increases lifespan and muscle pathology of Smn2B/– SMA mice
Table 2. SMN-dependent therapies in clinical trials*
Strategy Drug ClinicalTrials.gov identifier Clinical stage
SMN2 ISS-N1 targeting ASO Nusinersen/Spinraza NCT02386553
NCT02052791
NCT02865109
NCT01780246
NCT02462759
NCT01703988
NCT02193074
NCT02292537
NCT01839656
NCT02594124
NCT01494701
Active, Phase 2
Completed, Phase 1
Expanded access
Completed, Phase 1
Ongoing, Phase 2
Completed, Phase 1 and 2
Completed, Phase 3
Completed, Phase 3
Active, Phase 2
Enrolling by invitation, Phase 3
Completed, Phase 1
SMN2 targeting small molecules LMI070
RO7034067
Hydroxyurea
Celecoxib
NCT02268552
NCT03032172
NCT02913482
NCT02908685
NCT02633709
NCT00485511
NCT00568698
NCT00568802
NCT02876094
Active, Phase 1 and 2
Recruiting, Phase 2
Recruiting, Phase 2
Recruiting, Phase 2
Completed, Phase 1
Completed, Phase 2 and 3
Completed, Phase 1 and 2
Unknown, Phase 1 and 2
Not yet recruiting, Phase 2
SMN1 gene therapy AVXS-101 NCT02122952 Active, Phase 1
*As of June 2017.
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(Bowerman et al., 2010, 2012b). Additional investigators have
further confirmed the contribution of the RhoA-ROCK pathway to
SMA in neuronal cells (Hensel et al., 2014), patient fibroblasts
(Nölle et al., 2011) and glial cells (Caraballo-Miralles et al., 2012).
The tumour suppressor protein PTEN is a member of the protein
tyrosine phosphatase family that can regulate cell migration,
spreading and growth (Lachyankar et al., 2000; Li et al., 2003;
Sano et al., 1999; Tamura et al., 1999). Interestingly, PTEN is
phosphorylated by ROCK (Bermúdez Brito et al., 2015), thus
leading to increased PTEN inhibitory activity on neuronal survival.
While PTEN activity in SMAmice has yet to be investigated, we can
hypothesize that the increased activity of the RhoA-ROCK pathway
reported in SMA mice (Bowerman et al., 2010, 2012b) induces the
increased phosphorylation of PTEN. Concordantly, it has been
found that suppressing PTEN in SMA mice through a gene therapy
approach led to improvements in NMJ pathology and a significant
extension in lifespan (Little et al., 2015). Combined, these studies
have highlighted actin modulators as potential targets for
combinatorial therapeutic approaches for SMA.
Further regulators of actin dynamics have emerged as potential
therapeutic targets for SMA. Plastin 3 (PLS3) is an actin-bundling
protein that was identified as a modifier of disease severity in an
investigation of discordant family members that carried the same
SMN1 mutations (Oprea et al., 2008). Additional analyses of
serum (Yanyan et al., 2014) and iPSC-derived motor neurons from
SMA patients have further supported the influence of plastin 3
levels on disease progression in certain families but not others
(Boza-Morán et al., 2015; Heesen et al., 2016). Indeed,
overexpression of plastin 3 in a zebrafish model of SMA
significantly rescues the axonal growth and branching defects
caused by smn1 gene depletion (Oprea et al., 2008). Further
analysis of smn1mutant zebrafish reveals that reduced SMN levels
lead to decreased plastin 3 protein expression, NMJ defects and
aberrant motor function, and these effects can be corrected by
plastin 3 overexpression (Hao et al., 2012). More recently, studies
in mice have shown that increased expression of plastin 3 delays
axonal degeneration and improves NMJ function (Ackermann
et al., 2013) as well as ameliorates survival and neuromuscular
phenotype (Kaifer et al., 2017), possibly through the modulation
of endocytic pathways (Hosseinibarkooie et al., 2016). However, it
must be noted that a number of animal and patient studies do not
reflect the suggested modifying powers of plastin 3 on SMA
pathogenesis (McGovern et al., 2015; Stratigopoulos et al., 2010),
highlighting the complex relationship that may exist between SMN
and plastin 3. The pathological relevance and therapeutic
importance of non-SMN targets can be highly dependent on the
severity of the disease (Kaifer et al., 2017) and as such, should be
evaluated in hypomorphic models, whether transgenically or
pharmacologically induced. Nonetheless, the studies on RhoA-
ROCK, PTEN and plastin 3 have highlighted actin modulators as
potential targets for combinatorial therapeutic approaches for
SMA.
Subsequent work has also revealed other promising non-SMN
targets, including chondrolectin. It has been shown that this
transmembrane protein (encoded by Chodl) and its binding
partners are potential modifiers of axonal integrity in SMA mice
and that altered expression of Chodl is found in spinal motor
neurons of SMA mice (Bäumer et al., 2009). Importantly,
increasing the expression of chodl rescues motor neuron
outgrowth defects in a zebrafish model of SMA (Sleigh et al.,
2014). Experiments in mouse models are underway to fully evaluate
the therapeutic potential of Chodl modulation.
As described above, one of the housekeeping functions of SMN
is the regulation of RNA metabolism, particularly in the biogenesis
of snRNPs (Li et al., 2014), essential components of the RNA
splicing machinery (Will and Lührmann, 2001). It has been
demonstrated that SMN depletion specifically impacts the activity
of the spliceosome complex containing the U12 snRNP (Doktor
et al., 2017; Gabanella et al., 2007) and that the Drosophila
stasimon (stas) gene is a direct target of U12-dependent splicing
(Lotti et al., 2012). Stasimon (also known as Tmem41b in
mammals) plays a role in synaptic transmission in neuronal
synapses and its expression is significantly reduced and splicing
similarly altered in motor and sensory neurons of SMA mice (Lotti
et al., 2012). Importantly, overexpression of stas restored
neurotransmitter release in Drosophila smn mutants and rescued
motor axon growth and branching defects in an SMA zebrafish
model (Lotti et al., 2012).
The activity of cyclin-dependent kinase 5 (Cdk5) has been reported
to be upregulated in SMA mice and patient iPSC-derived motor
neurons (Miller et al., 2015). The increased abundance of Cdk5 is
responsible for the pathological hyperphosphorylation of the tau
protein in SMN-depleted neuronal cells (Miller et al., 2015). A
transgenic approach was used to completely knockout Cdk5
expression in SMA mice, which led to significant rescue of motor
neuron synaptic stripping, motor neuron death and NMJ denervation
(Miller et al., 2015). Interestingly, a recent unbiased RNA-
sequencing-based assessment of global gene changes in SMN-
depleted mouse tissues confirmed the specific missplicing of U12
snRNP-dependent genes, several ofwhich areCa2+ channel genes and
may beupstream regulators ofCdk5activity (Doktoret al., 2017), thus
further highlighting Cdk5 as a potential pathological effector in SMA.
Finally, the ubiquitin-like modifier activating enzyme Uba1
(Groen and Gillingwater, 2015) and its downstream effectors
[including the Wnt signaling effector β-catenin (Ctnnb1)], have
been identified as major targets acting downstream of SMN to
regulate neuromuscular and systemic pathology in SMA. Reduced
levels of Uba1 were reported in all tissues and organs investigated
from SMA mouse models (Aghamaleky Sarvestany et al., 2014;
Wishart et al., 2014). Furthermore, β-catenin, which accumulates in
neuromuscular tissues in SMA, has been uncovered as a key
downstream target of Uba1 deficiencies in SMA. Importantly,
pharmacological inhibition of β-catenin dramatically ameliorated
neuromuscular pathology in zebrafish, Drosophila and mouse
models of SMA (Wishart et al., 2014) while systemic Uba1 gene
therapy increased survival and improved neuromuscular and
peripheral pathology of SMA mice (Powis et al., 2016).
Thus, a range of pathways are already candidates for non-SMN
therapy approaches. As the list of molecular effectors grows, drug-
screening approaches to identify pharmacological compounds that
can modulate them will be essential. In addition, identifying novel
targets should combine proteomics and transcriptomics studies with
genome-based network analysis and drug-repositioning strategies.
Combinatorial experimental paradigms should then be put in place
to evaluate the therapeutic potential of a ‘cocktail treatment’
comprising SMN gene therapy and a non-SMN-targeting drug,
optimally making use of the multiple in vitro and in vivo models
discussed above (Fig. 3). While several non-SMN pathways and
molecular targets have been highlighted as being aberrantly
regulated in SMA models and display therapeutic potential, these
studies remain, for the most part, in the pre-clinical discovery phase,
in contrast to SMN-dependent strategies that are quickly dominating
the clinical trial landscape. For non-SMN treatments to become a
practical reality in the combinatorial approach paradigm, an
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efficient strategic plan needs to be established to facilitate their
transition to the clinic.
Improving systemic delivery of drugs to target CNS and non-
CNS tissues
While motor neurons are undoubtedly the primary cellular target in
SMA (Powis and Gillingwater, 2016), cumulative evidence
highlights the role of other cells and tissues that may be clinically
or sub-clinically affected. However, most of these studies have
investigated these tissues or cells independently of the others. The
hierarchal contribution of each to Type 0-IV SMA therefore remains
unclear. While current gene therapies in clinical trials are promising,
nusinersen (Ionis Pharmaceuticals/Biogen) delivery circumvents
the peripheral tissues and organs by being injected directly to the
CNS, and, although AAV9-SMN1 gene therapy (AveXis) can be
delivered systemically, multiple rounds of administration might not
be possible due to immunogenicity (Basner-Tschakarjan and
Mingozzi, 2014). In both of these cases, this raises the risk of
incomplete rescue of SMN deficiency in peripheral organs and the
potential for development of non-CNS pathologies later in life.
Development of novel therapeutic approaches targeting non-
SMN targets should therefore include careful consideration of both
CNS and systemic delivery methods. The optimal dosing regimen
for a pharmacological compound should balance its ability to
target all relevant tissues with the need to make therapy as non-
invasive as possible. An option for systemic delivery of molecules is
to conjugate them with a vehicle that can transport them across the
membrane of multiple cell types. This has proven efficient for the
delivery of ASOs under the neutrally charged chemistry of
phosphorodiamidate morpholino (PMO) (Douglas and Wood,
2013). Cell-penetrating peptides (CPPs) have previously been
shown to cross both plasma and endosomal membranes (Mitchell
et al., 2000). One such peptide-conjugated PMO has been
developed, termed peptide nucleic acids/PMO internalization
peptide 6a (Pip6a)-PMO, that efficiently modulates splicing in
various tissues of a DMD mouse model (Betts et al., 2012).
Importantly, it is delivered via a single intravenous (IV) injection.
Recently, it has been reported that conjugation of Pip6a to the SMN2
ISS-N1 PMO results in dramatic improvements in survival and
neuromuscular phenotype associated with increased FL-SMN
levels in both CNS and peripheral tissues (Hammond et al.,
2016). CPPs therefore have significant potential to facilitate
targeting of SMN to the whole body as well the eventual delivery
of therapeutic non-SMN targets or drugs in a similar fashion.
Concluding remarks
Gene therapy and ASO approaches to increase SMN levels are now
entering the clinical arena. In the severest form (Type I) of SMA,
promising preliminary results must be balanced with a full
appreciation of the potential limitations of such strategies. The
value of SMN-based therapies in older Type II and III patients is
unclear and it may be some time before these can be accurately
evaluated. Translational research should therefore address the
development of non-CNS and SMN-independent therapeutic
approaches to complement and enhance the benefits of CNS-
directed and SMN-dependent therapies, taking into account the
need to maintain the neuromuscular system of an SMA patient
through childhood and puberty, when there is maximal growth of
the axial skeleton, and into adult life when the process of age-related
attrition of motor units is likely to contribute to progressive loss of
motor function (Fig. 4).
There remains a need for the use of various in vitro and in vivo
models as well as molecular high-throughput approaches for
the rapid identification of new targets and drugs. It will be
crucial to develop tools to evaluate the effects of combination
pharmacological therapies at different disease stages. It is therefore
of utmost importance that the SMA research and clinical
community, as well as those living with SMA, recognise the need
to develop and test combinatorial therapeutic approaches that can be
effectively delivered systemically and target both SMN and non-
SMNmolecular effectors. This will allow for a better understanding
of the tissue requirements for SMN and non-SMN treatments and,
In utero 0-3 years 4-16 years 
Gene therapy 
Type 0 
Type I 
Type II 
Type III Type IV 
Antisense oligonucleotides 
Neuromuscular
development  Pubertal growth
spurt 
Age-related
loss of motor units
Childhood
growth
CNS requirement for SMN 
Drugs enhancing neuromuscular development 
Drugs promoting neuromuscular maintenance 
Prevention of neurodegeneration 
Adulthood 
?
Fig. 4. Overview of the natural history of spinal muscular atrophy (SMA), major developmental milestones and treatment strategies. Although the
precise details of SMN expression in the developing human nervous system are difficult to study, evidence from animal models suggests that SMN levels
peak in the period of maximum neuromuscular development and then decline to a stable low level. This means that there are different windows of opportunity
for the various types of proposed therapies to be effectively employed. Whether combinatorial therapies might be particularly applicable in the more chronic
phase of SMA or from the outset is a priority area for research. ASO therapy in utero will be dependent on an optimal route of delivery, which at present
remains unclear.
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ultimately, provide the best therapeutic strategy for SMA. As with
most chronic progressive neurodegenerative disorders, it is likely
that, once loss of neuronal integrity has been initiated, combinatorial
approaches to therapy will be required to maintain neuromuscular
health throughout life.
This article is part of a special subject collection ‘Neurodegeneration: fromModels to
Mechanisms to Therapies’, which was launched in a dedicated issue guest edited by
Aaron Gitler and James Shorter. See related articles in this collection at http://dmm.
biologists.org/collection/neurodegenerative-disorders.
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